Richard I Fisher
Overview
Explore the profile of Richard I Fisher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
134
Citations
15475
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gerson J, Handorf E, Villa D, Gerrie A, Chapani P, Li S, et al.
Blood Adv
. 2023 Oct;
7(24):7393-7401.
PMID: 37874912
Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma; data indicate that blastoid and pleomorphic variants have a poor prognosis. We report characteristics and outcomes of patients with blastoid/pleomorphic variants...
2.
Shulman R, Weinberg D, Ross E, Ruth K, Rall G, Olszanski A, et al.
J Natl Compr Canc Netw
. 2022 Feb;
20(2):160-166.
PMID: 35130494
Background: Most safety and efficacy trials of the SARS-CoV-2 vaccines excluded patients with cancer, yet these patients are more likely than healthy individuals to contract SARS-CoV-2 and more likely to...
3.
McNiff K, Caligiuri M, Davidson N, Farrar W, Fisher R, Glimcher L, et al.
Oncologist
. 2021 Jun;
26(7):533-536.
PMID: 34076924
No abstract available.
4.
Persky D, Li H, Stephens D, Park S, Bartlett N, Swinnen L, et al.
J Clin Oncol
. 2020 Jul;
38(26):3003-3011.
PMID: 32658627
Purpose: Diffuse large B-cell lymphoma (DLBCL) presents as a limited-stage disease in 25% to 30% of patients, with better overall survival (OS) than that for advanced-stage disease but with continuous...
5.
Kutikov A, Weinberg D, Edelman M, Horwitz E, Uzzo R, Fisher R
Ann Intern Med
. 2020 Mar;
172(11):756-758.
PMID: 32219410
No abstract available.
6.
Fisher R
J Natl Compr Canc Netw
. 2019 Nov;
17(11.5):1414-1416.
PMID: 31766017
Over the past several decades, tremendous progress has been made in the treatment of follicular lymphoma. The addition of rituximab to chemotherapy led to significant improvements in survival in the...
7.
Dasmahapatra G, Lembersky D, Son M, Patel H, Peterson D, Attkisson E, et al.
Mol Cancer Ther
. 2019 Jun;
18(6):1180.
PMID: 31160510
No abstract available.
8.
Dasmahapatra G, Lembersky D, Son M, Attkisson E, Dent P, Fisher R, et al.
Mol Cancer Ther
. 2019 Jun;
18(6):1179.
PMID: 31160509
No abstract available.
9.
Barta S, Zain J, MacFarlane 4th A, Smith S, Ruan J, Fung H, et al.
Clin Lymphoma Myeloma Leuk
. 2019 Apr;
19(6):356-364.e3.
PMID: 31029646
Background: Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) are frequently expressed in T-cell lymphomas. This provides a rationale for exploration of immune checkpoint inhibitors in the management of...
10.
Bartlett N, Wilson W, Jung S, Hsi E, Maurer M, Pederson L, et al.
J Clin Oncol
. 2019 Apr;
37(21):1790-1799.
PMID: 30939090
Purpose: Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study, compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as frontline...